Triple agonism at GLP-1, GIP and glucagon receptors is the defining feature and the glucagon limb is the one people find counter-intuitive. It raises energy expenditure and promotes hepatic fat oxidation, and the incretin limbs offset the glycaemic consequence.
The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it.
I would like to disagree carefully with the settled view on glucagon receptor agonist, and I would like to be argued out of it if the disagreement is bad.
The disagreement is about one step, not about the conclusion. If the step holds I withdraw it entirely.
The reason glucagon receptor agonist keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
Reading back through the glucagon receptor agonist threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
That reframing is the whole thing. The facts I already had.
The arithmetic in post #3 is right; the assumption feeding it is the part to check.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
That much is documented. The rest is how I have interpreted it.
Triple agonism at GLP-1, GIP and glucagon receptors is the defining feature and the glucagon limb is the one people find counter-intuitive. It raises energy expenditure and promotes hepatic fat oxidation, and the incretin limbs offset the glycaemic consequence.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make claims about safety profile is using the trial for a purpose it was not designed for.
Nothing above should be read as advice about what anyone else should do.
Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that translates to improved clinical outcomes is being tested in phase 2 work.
That is all I can say without guessing.
Adding a small correction to the glucagon receptor agonist summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.
On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference standard in wide circulation and no published impurity profile to compare against.
A guess, clearly labelled as one.
This is the first time the answer has come with its own limits attached. Appreciated.
Whatever the answer on glucagon receptor agonist turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
The version of glucagon receptor agonist that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
The hepatic-steatosis rationale follows directly from glucagon receptor agonism promoting fat oxidation in the liver. Mechanistic plausibility in this field has a poor record of predicting clinical outcomes, which is why the trials matter more than the mechanism.
Two sources, same conclusion, and I could not rule out that one copied the other.
Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.
If anyone can point at the primary source I would be grateful.
Post #18 put the caveat in the right place and I want to underline it.
Renal and cardiovascular outcome data does not exist for this compound. Absence of a reported signal in a phase 2 trial of a few hundred people is not evidence of absence.
None of the above is medical advice and I am not qualified to give any.
Everything in post #19 holds. The case it does not cover is the one I have.
On identity confirmation more generally: for a compound with no widely available reference material, orthogonal confirmation matters more than usual. A mass result and a chromatographic result together say considerably more than either alone.
That holds under the stated conditions and I have stated them.
I changed my mind about glucagon receptor agonist after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.
Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that translates to improved clinical outcomes is being tested in phase 2 work.
I have changed my mind on this once already, so take it as current rather than settled.
Where I part company with post #23, and it is a narrow parting.
A request rather than an answer: could whoever has the primary source for glucagon receptor agonist post it? I have seen the claim three times this month and each version had lost a qualifier.
Post #27 is the version of this I will quote in future. One addition.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
I looked this up rather than remembered it, which is the right order.
I keep a log for glucagon receptor agonist specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.